ASX:HPC
Hydration Pharmaceuticals Co Ltd Fully Paid Ord. Shrs
Investment Summary
The fund managers believe that Hydration Pharmaceuticals Co Ltd (HPC) is showing promising signs of growth, particularly in its US operations. In their opinion, the company's Liver Detox product has experienced impressive growth, which, coupled with a strong focus on cost management, is contributing to consistent improvements in EBITDA. This progress has bolstered HPC's confidence in achieving sustainable profitability in the US market within the next 12 months. While the company’s share price remains modest, the fund managers are optimistic about HPC’s trajectory, noting that the ongoing financial improvements and operational efficiencies are key factors driving the company’s potential for success. Overall, the fund managers see HPC as a company that could reach a more stable financial position, contingent upon the continued performance of its flagship product and successful cost control measures.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Manager
Saville Capital
Date
30 Nov 2024
Price
$0.02
Medium
Monthly Report
Commentary
Saville Capital Emerging Companies Fund continues to maintain a positive outlook on Hydration Pharmaceuticals Co Ltd, emphasizing the impressive growth trajectory of its Liver Detox product in the US market. The company’s commitment to effective cost management is contributing to consistent monthly increases in EBITDA. This financial improvement enhances the fund's confidence in HPC’s potential to achieve sustainable profitability in its ongoing US operations over the next year. The strategic focus on expanding product reach while optimizing operational efficiencies positions Hydration Pharmaceuticals well for future success, reinforcing the fund's investment thesis in this emerging sector.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.